Search clinical trials for: KX2-391 Ointment 1%

Total 252 results

Almirall, S.A.
Athenex, Inc.

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003)

Actinic Keratoses

United States
Almirall, S.A.
Athenex, Inc.

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

Actinic Keratosis

United States
Athenex, Inc.
TKL Research, Inc.

Completed

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratoses

United States
Almirall, S.A.
Athenex, Inc.

Completed

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

Actinic Keratosis

United States
Athenex, Inc.

Completed

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

Actinic Keratosis

United States
Athenex, Inc.

Completed

Evaluation of KX2-391 in Patients With Advanced Malignancies

Lymphoma | Solid Tumors

United States
Kinex Pharmaceuticals Inc.

Completed

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

Acute Myelogenous Leukemia

United States
Athenex, Inc.

Completed

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Bone-Metastatic, Castration-Resistant Prostate Cancer

United States
PharmaEssentia
PharmaEssentia Japan K.K.

Completed

Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

Healthy Volunteer

Japan
Pfizer

Completed

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Dermatitis, Atopic

Australia
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Atopic Dermatitis

Japan
Roswell Park Cancer Institute

Completed

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Lymphoproliferative Disorder

United States
Athenex, Inc.

Completed

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

Advance Malignancies

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Hovione Scientia Limited

Completed

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

Meibomian Gland Dysfunction | MGD-Meibomian Gland Dysfunction

United States
PharmaEssentia
PharmaEssentia Japan K.K.

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Actinic Keratosis

Japan
Ziarco Pharma Ltd

Completed

A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
GlaxoSmithKline

Completed

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

Skin Infections, Bacterial

United States, South Africa, India, Argentina, Brazil
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD

Atopic Dermatitis (AD)

China
Technoderma Medicines Inc.
Therapeutics, Inc.

Not yet recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
Medimetriks Pharmaceuticals, Inc

Completed

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Honduras, Panama
GlaxoSmithKline

Completed

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

Skin Infections, Bacterial

Netherlands, Costa Rica, Germany, Mexico, Canada, India, Poland, South Africa, France, Peru
Oneness Biotech Co., Ltd.

Completed

The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers

Diabetic Foot

Taiwan
GlaxoSmithKline

Completed

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

Skin Infections, Bacterial

United States, Germany, Taiwan, Netherlands, Argentina, Chile, Costa Rica, South Africa, Mexico
GlaxoSmithKline

Completed

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Impetigo

India, Mexico, Netherlands, Italy, Peru
Austin Institute for Clinical Research

Recruiting

Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Superficial Basal Cell Carcinoma

United States
DermaGen AB

Completed

A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060

Atopic Dermatitis

Sweden
Circassia Limited
Bioskin GmbH

Completed

Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Atopic Dermatitis (AD)

China
Dong-A University Hospital

Completed

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

Colorectal Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer

Korea, Republic of
HK inno.N Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Mild to Moderate Atopic Dermatitis
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Hanmi Pharmaceutical Company Limited

Unknown

A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors

Breast Cancer | Gastric Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Korea, Republic of
Novartis Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

Erythemato-telangiectatic Rosacea

United States
Sensei Biotherapeutics, Inc.
Accelovance

Completed

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Prostate Cancer

United States
Pfizer

Completed

CP-690-550 Ointment For Chronic Plaque Psoriasis

Psoriasis

United States, Canada
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males (TreatAIN)

High-grade Anal Intraepithelial Neoplasia
Emory University
Georgia Center for Oncology Research & Education

Not yet recruiting

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

Human Immunodeficiency Virus | Human Papilloma Virus | Anal Intraepithelial Neoplasia | High-Grade Squamous Intraepithelial Lesions

United States
University of Oklahoma

Not yet recruiting

CBD Effects on Forehead Split Scar Healing

Forehead; Wound
Castle Creek Pharmaceuticals, LLC

Completed

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Dystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)

United States
Castle Creek Pharmaceuticals, LLC
TKL Research, Inc.

Completed

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

Healthy

United States
Castle Creek Pharmaceuticals, LLC

Completed

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

Healthy

United States
Castle Creek Pharmaceuticals, LLC

Completed

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

Healthy

United States
BioMarin Pharmaceutical

Recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

United States, Spain, Australia
Flame Biosciences

Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Gastric Cancer | Solid Tumor | Pancreas Cancer
Castle Creek Pharmaceuticals, LLC

Completed

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

Healthy

United States
Ferrer Internacional S.A.

Completed

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Impetigo

Germany, South Africa
TWi Biotechnology, Inc.

Terminated

A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid

Bullous Pemphigoid

Taiwan
Castle Creek Pharmaceuticals, LLC

Completed

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Epidermolysis Bullosa | Epidermolysis Bullosa Simplex

United States
Sohag University

Unknown

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Vitiligo | Tacrolimus

Egypt

3

Subscribe